This article contributes to the studies about CSR reporting in the pharmaceutical industry, aiming to understand whether COVID-19 vaccine producers have used an impression management strategy during the pandemic emergency. This research was focused on CSR reports of vaccine producers in 2020 and 2021, having applied a content analysis method. This study investigated the quantitative amount of disclosure and qualitatively, the thematic topics connected to a possible impression management strategy. This research revealed that vaccine producers used a proactive approach to preserve and reinforce their reputation. The topics analyzed in the CSR reports appeared selected to influence the development of a global acceptance from vaccine producers’ stakeholders. This research contributes to filling the knowledge gap about CSR reporting in the pharmaceutical industry, a topic that has received limited attention in the literature. Moreover, we conducted one of the first studies about impression management in CSR reporting in the pharmaceutical sector and also considered a different perspective relative to previous studies in impression management research. Indeed, we investigated the use of impression management in a pre-crisis phase, which is a fundamental moment to creating resilience for a stakeholder-reaction to negative events.
CSR reporting in the pharmaceutical industry and pre-crisis com-munication. An impression management perspective
	
	
	
		
		
		
		
		
	
	
	
	
	
	
	
	
		
		
		
		
		
			
			
			
		
		
		
		
			
			
				
				
					
					
					
					
						
							
						
						
					
				
				
				
				
				
				
				
				
				
				
				
			
			
		
			
			
				
				
					
					
					
					
						
						
							
							
						
					
				
				
				
				
				
				
				
				
				
				
				
			
			
		
			
			
				
				
					
					
					
					
						
							
						
						
					
				
				
				
				
				
				
				
				
				
				
				
			
			
		
		
		
		
	
Alberto Romolini
;Elena Gori
	
		
		
	
			2024-01-01
Abstract
This article contributes to the studies about CSR reporting in the pharmaceutical industry, aiming to understand whether COVID-19 vaccine producers have used an impression management strategy during the pandemic emergency. This research was focused on CSR reports of vaccine producers in 2020 and 2021, having applied a content analysis method. This study investigated the quantitative amount of disclosure and qualitatively, the thematic topics connected to a possible impression management strategy. This research revealed that vaccine producers used a proactive approach to preserve and reinforce their reputation. The topics analyzed in the CSR reports appeared selected to influence the development of a global acceptance from vaccine producers’ stakeholders. This research contributes to filling the knowledge gap about CSR reporting in the pharmaceutical industry, a topic that has received limited attention in the literature. Moreover, we conducted one of the first studies about impression management in CSR reporting in the pharmaceutical sector and also considered a different perspective relative to previous studies in impression management research. Indeed, we investigated the use of impression management in a pre-crisis phase, which is a fundamental moment to creating resilience for a stakeholder-reaction to negative events.| File | Dimensione | Formato | |
|---|---|---|---|
| 
									
										
										
										
										
											
												
												
												    
												
											
										
									
									
										
										
											Romolini et al 2-2024.pdf
										
																				
									
										
											 non disponibili 
											Tipologia:
											Versione Editoriale (PDF)
										 
									
									
									
									
										
											Licenza:
											
											
												NON PUBBLICO - Accesso privato/ristretto
												
												
												
											
										 
									
									
										Dimensione
										3.44 MB
									 
									
										Formato
										Adobe PDF
									 
										
										
								 | 
								3.44 MB | Adobe PDF | Visualizza/Apri Richiedi una copia | 
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
